BÁRTŮ KENDALL, Michaela, Kristýna NĚMEJCOVÁ, Romana MICHÁLKOVÁ, Quang Hiep BUI, Jana DROZENOVÁ, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATĚJ, Gábor MÉHES, Adam ŠAFANDA, Naveena SINGH, Petr ŠKAPA, Zuzana ŠPŮRKOVÁ, Simona STOLNICU, Marián ŠVAJDLER, Sigurd F LAX, W Glenn MCCLUGGAGE and Pavel DUNDR. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases. International Journal of Gynecological Pathology. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2024. ISSN 0277-1691. Available from: https://dx.doi.org/10.1097/PGP.0000000000000962.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases
Authors BÁRTŮ KENDALL, Michaela, Kristýna NĚMEJCOVÁ, Romana MICHÁLKOVÁ, Quang Hiep BUI, Jana DROZENOVÁ, Pavel FABIAN, Oluwole FADARE, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATĚJ, Gábor MÉHES, Adam ŠAFANDA, Naveena SINGH, Petr ŠKAPA, Zuzana ŠPŮRKOVÁ, Simona STOLNICU, Marián ŠVAJDLER, Sigurd F LAX, W Glenn MCCLUGGAGE and Pavel DUNDR.
Edition International Journal of Gynecological Pathology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2024, 0277-1691.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30109 Pathology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.400 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1097/PGP.0000000000000962
UT WoS 999
Keywords in English INSM1; Synaptophysin; Chromogranin; Immunohistochemistry; Ovarian Tumors
Tags 14110230
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 29/2/2024 14:07.
Abstract
Expression of neuroendocrine (NE) markers in primary ovarian non-NE epithelial tumors has rarely been evaluated. The aim of our study was to evaluate the expression of the most widely used NE markers in these neoplasms and to determine any prognostic significance of NE marker expression. The cohort consisted of 551 primary ovarian tumors, including serous borderline tumors, low-grade serous carcinomas, high-grade serous carcinomas (HGSC), clear cell carcinomas, endometroid carcinomas, mucinous borderline tumors, and mucinous carcinomas. Immunohistochemical analysis was performed using antibodies against INSM1, synaptophysin, chromogranin, and CD56 on tissue microarray. Positivity for INSM1, synaptophysin, chromogranin, and CD56 was most frequently observed in mucinous tumors (48.7%, 26.0%, 41.5%, and 100%, respectively). The positivity for these NE markers was mostly restricted to nonmucinous elements distributed throughout the tumor. The mucinous borderline tumor and mucinous carcinomas groups had similar proportions of positivity (mucinous borderline tumor: 53%, mucinous carcinomas: 39%). In the other tumor types, except for HGSC, there was only focal expression (5%–10%) or negativity for NE markers. HGSC showed high CD56 expression (in 26% of cases). Survival analysis was only performed for CD56 in HGSC as this was the only group with sufficient positive cases, and it showed no prognostic significance. Except for mucinous tumors, expression of NE markers in non-NE ovarian epithelial tumors is low. CD56 expression in HGSC occurs frequently but is without diagnostic or prognostic value.
Links
90125, large research infrastructuresName: BBMRI-CZ III
PrintDisplayed: 10/5/2024 15:23